Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;9(5):e1001213.
doi: 10.1371/journal.pmed.1001213. Epub 2012 May 8.

Six-year follow-up of impact of co-proxamol withdrawal in England and Wales on prescribing and deaths: time-series study

Affiliations

Six-year follow-up of impact of co-proxamol withdrawal in England and Wales on prescribing and deaths: time-series study

Keith Hawton et al. PLoS Med. 2012.

Abstract

Background: The analgesic co-proxamol (paracetamol/dextropropoxyphene combination) has been widely involved in fatal poisoning. Concerns about its safety/effectiveness profile and widespread use for suicidal poisoning prompted its withdrawal in the UK in 2005, with partial withdrawal between 2005 and 2007, and full withdrawal in 2008. Our objective in this study was to assess the association between co-proxamol withdrawal and prescribing and deaths in England and Wales in 2005-2010 compared with 1998-2004, including estimation of possible substitution effects by other analgesics.

Methods and findings: We obtained prescribing data from the NHS Health and Social Care Information Centre (England) and Prescribing Services Partneriaeth Cydwasanaethau GIG Cymru (Wales), and mortality data from the Office for National Statistics. We carried out an interrupted time-series analysis of prescribing and deaths (suicide, open verdicts, accidental poisonings) involving single analgesics. The reduction in prescribing of co-proxamol following its withdrawal in 2005 was accompanied by increases in prescribing of several other analgesics (co-codamol, paracetamol, codeine, co-dydramol, tramadol, oxycodone, and morphine) during 2005-2010 compared with 1998-2004. These changes were associated with major reductions in deaths due to poisoning with co-proxamol receiving verdicts of suicide and undetermined cause of -21 deaths (95% CI -34 to -8) per quarter, equating to approximately 500 fewer suicide deaths (-61%) over the 6 years 2005-2010, and -25 deaths (95% CI -38 to -12) per quarter, equating to 600 fewer deaths (-62%) when accidental poisoning deaths were included. There was little observed change in deaths involving other analgesics, apart from an increase in oxycodone poisonings, but numbers were small. Limitations were that the study was based on deaths involving single drugs alone and changes in deaths involving prescribed morphine could not be assessed.

Conclusions: During the 6 years following the withdrawal of co-proxamol in the UK, there was a major reduction in poisoning deaths involving this drug, without apparent significant increase in deaths involving other analgesics.

PubMed Disclaimer

Conflict of interest statement

KH and SS were temporary advisors to the MHRA for its evaluation of the efficacy and safety profile of co-proxamol. CW works for the Office for National Statistics. All other authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Trends in prescriptions dispensed for co-proxamol and seven other analgesics in England and Wales, 1998–2010.
Figure 2
Figure 2. Deaths in England and Wales from poisoning with co-proxamol and other analgesics, 1998–2010.
Suicide and open verdicts, substances taken alone, with or without alcohol.

References

    1. Medicines and Healthcare products Regulatory Agency. Withdrawal of co-proxamol products and interim updated prescribing information CEM/CMO/2005/2. 2005. Available: http://www.mhra.gov.uk/home/groups/pl-a/documents/websiteresources/con01.... Accessed 2 March 2005.
    1. Committee on Safety of Medicines. Withdrawal of co-proxamol (Distalgesic, Cosalgesic, Dolgesic). Current Problems in Pharmacovigilance. 2006;31:11–11.
    1. Simkin S, Hawton K, Sutton L, Gunnell D, Bennewith O, et al. Co-proxamol and suicide: a review to inform initiatives to prevent the continuing toll of overdose deaths. Q J Med. 2005;98:159–170. - PubMed
    1. Hawton K, Simkin S, Deeks JJ. Co-proxamol and suicide: a study of national mortality statistics and local non-fatal self-poisonings. BMJ. 2003;326:1006–1008. - PMC - PubMed
    1. Drug and Therapeutics Bulletin. Distalgesic and its equivalents: time for action. Drug Ther Bull. 1983;21:17–19. - PubMed

Publication types